AI RNA Therapies Target Drug Discovery's Core Challenges
Podcast guests highlight how AI models enable Ochre Bio's RNA therapies for chronic liver disease, offering strategic insights into longstanding drug discovery problems.

Created by Terri Foster (Guh gub)
Curated AI breakthroughs in healthcare, robotics, finance with concise case studies and learning summaries
Explore the latest content tracked by AI Impact Curator
Podcast guests highlight how AI models enable Ochre Bio's RNA therapies for chronic liver disease, offering strategic insights into longstanding drug discovery problems.
Sylvester Comprehensive Cancer Center is actively embedding ambient AI tools like Suki into clinical workflows, enabling physicians to focus on...
Sino Biological's XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast in vitro production of antibodies like VHH and scFv in just 3 hours,...
Multimodal AI for medical diagnostics is advancing beyond early frameworks toward real-world clinical testing.
Two complementary advances are tackling the core bottlenecks of data scarcity and privacy in medical imaging AI.
Widespread use of invalid statistical tests undermines biomedical machine learning research. This critical paper is essential reading for anyone building or evaluating models in healthcare AI.
Natural language search now lets scientists query lab samples in plain English, such as “tubes from freezer XYZ last week,” while preserving full...
Concept Life Sciences and OpenBench launched a joint AI-driven hit discovery platform to help biotechs identify drug candidates faster.
Healthcare data complexity is driving a shift toward agentic AI systems that span EMR platforms and advanced sequencing.
Three parallel advances signal rapid AI-robotics integration across research, deployment, and accessibility.
Industry groups call for modernizing third-party risk frameworks to match today's AI-driven vendor landscape.
Experts caution that AI's biggest near-term value lies in avoiding knowable mistakes in planning rather than slashing clinical failure rates, since...
AI is reshaping microscopy at opposite scales:
AI is reshaping radiology at both diagnostic and operational levels for a more complete overhaul.
Major collaborations are rapidly building the data and compute foundations for AI-driven target identification in biomedicine.
AI is reshaping clinical trial operations through enhanced RBQM and data stewardship:
Maestro trains a lightweight RL policy to dynamically select and compose frozen expert models with a hierarchical skill library, reframing multimodal...